Acadia Pharmaceuticals (ACAD) Capital Expenditures (2012 - 2026)

Acadia Pharmaceuticals' Capital Expenditures history runs 13 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• In Q1 2026, Capital Expenditures changed N/A year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $9.9 million (up 1793.31% YoY), while the FY2025 annual figure was $4.7 million, up 796.75% from the prior year.
• Capital Expenditures was $5.2 million for Q1 2026 at Acadia Pharmaceuticals, up from $4.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $5.2 million in Q1 2026 to a low of $70000.0 in Q3 2024.
• Historically, Capital Expenditures has averaged $1.7 million across 3 years, with a median of $420500.0 in 2024.
• Biggest YoY gain for Capital Expenditures was 784.11% in 2025; the steepest drop was 454.29% in 2025.
• A 3-year view of Capital Expenditures shows it stood at $453000.0 in 2024, then soared by 784.11% to $4.0 million in 2025, then soared by 30.14% to $5.2 million in 2026.
• The last three Capital Expenditures figures came in at $5.2 million (Q1 2026), $4.0 million (Q4 2025), and $388000.0 (Q3 2025), per Business Quant data.